Florida paid $82M for a Canadian drug program that never imported a drug to a Lakeland Warehouse

By Staff

Florida signed an $82 million contract with LifeScience Logistics to manage the program and maintain a specialized, 100,000 sq-foot climate-controlled warehouse facility in Lakeland, Florida.

Despite state expenditures—which reached over $50 million to $82 million under the contracted budget—no prescription medications have been imported or distributed through the Lakeland facility.

Key Factors Behind the Stall

• Federal & Regulatory Delays: Governor Ron DeSantis signed the drug importation initiative into law in 2019, but federal clearance took years. Although the U.S. FDA granted conditional approval in January 2024, the state must still fulfill strict pre-import requirements, including supply chain tracing and batch testing.
• Canadian Export Restrictions: In response to U.S. state importation proposals, the Canadian federal government instituted export restrictions to safeguard its own domestic drug supply from potential shortages, creating significant hurdles for U.S. states attempting to secure Canadian suppliers.
• Manufacturer & Supplier Resistance: Major pharmaceutical manufacturers have resisted participating in state importation programs or selling drugs at Canadian rates meant for export into the U.S. market.
• Facility Costs: While the Lakeland warehouse was constructed and maintained to meet FDA security and temperature-control standards, it has remained largely unutilized for its primary intended purpose while ongoing maintenance costs continue.